Matthew Plunkett - Net Worth and Insider Trading

Matthew Plunkett Net Worth

The estimated net worth of Matthew Plunkett is at least $536,383 dollars as of 2024-11-13. Matthew Plunkett is the EVP, Chief Business Officer of CTI BioPharma Corp and owns about 59,008 shares of CTI BioPharma Corp (CTIC) stock worth over $536,383. Details can be seen in Matthew Plunkett's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew Plunkett has not made any transactions after 2016-03-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Matthew Plunkett

To

Matthew Plunkett Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matthew Plunkett owns 3 companies in total, including Nkarta Inc (NKTX) , CTI BioPharma Corp (CTIC) , and Imago BioSciences Inc (IMGO) .

Click here to see the complete history of Matthew Plunkett’s form 4 insider trades.

Insider Ownership Summary of Matthew Plunkett

Ticker Comapny Transaction Date Type of Owner
NKTX Nkarta Inc 2020-07-09 Chief Financial Officer
CTIC CTI BioPharma Corp 2016-03-04 EVP & Corporate Development
IMGO Imago BioSciences Inc 2021-07-15 Chief Financial Officer

Matthew Plunkett Latest Holdings Summary

Matthew Plunkett currently owns a total of 1 stock. Matthew Plunkett owns 59,008 shares of CTI BioPharma Corp (CTIC) as of March 4, 2016, with a value of $536,383.

Latest Holdings of Matthew Plunkett

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CTIC CTI BioPharma Corp 2016-03-04 59,008 9.09 536,383

Holding Weightings of Matthew Plunkett


Matthew Plunkett Form 4 Trading Tracker

According to the SEC Form 4 filings, Matthew Plunkett has made a total of 0 transactions in CTI BioPharma Corp (CTIC) over the past 5 years. The most-recent trade in CTI BioPharma Corp is the sale of 1,000 shares on March 4, 2016, which brought Matthew Plunkett around $5,900.

Insider Trading History of Matthew Plunkett

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Matthew Plunkett Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Matthew Plunkett Ownership Network

Ownership Network List of Matthew Plunkett

No Data

Ownership Network Relation of Matthew Plunkett

Insider Network Chart

Matthew Plunkett Owned Company Details

What does Nkarta Inc do?

Who are the key executives at Nkarta Inc?

Matthew Plunkett is the Chief Financial Officer of Nkarta Inc. Other key executives at Nkarta Inc include Chief Legal Officer Alicia J. Hager , Chief Medical Officer David Shook , and Sr. VP & Technical Operations Ralph Brandenberger .

Nkarta Inc (NKTX) Insider Trades Summary

Over the past 18 months, Matthew Plunkett made no insider transaction in Nkarta Inc (NKTX). Other recent insider transactions involving Nkarta Inc (NKTX) include a net sale of 9,598 shares made by James Trager , a net sale of 9,378 shares made by Alicia J. Hager , and a net sale of 5,778 shares made by David Shook .

In summary, during the past 3 months, insiders sold 0 shares of Nkarta Inc (NKTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 41,413 shares of Nkarta Inc (NKTX) were sold and 5,000,000 shares were bought by its insiders, resulting in a net purchase of 4,958,587 shares.

Nkarta Inc (NKTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Nkarta Inc Insider Transactions

No Available Data

Matthew Plunkett Mailing Address

Above is the net worth, insider trading, and ownership report for Matthew Plunkett. You might contact Matthew Plunkett via mailing address: 3101 Western Avenue, Suite 600, Seattle Wa 98121.